Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of the Efficacy Safety and Tolerability of Nitric Oxide Given Intermittently Via Inhalation to Subjects With Bronchiolitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03053388
Recruitment Status : Completed
First Posted : February 15, 2017
Last Update Posted : July 9, 2019
Sponsor:
Information provided by (Responsible Party):
Beyond Air Inc.

Brief Summary:

Double blind, randomized multi-center, evaluation of the efficacy, safety and tolerability of Nitric Oxide (NO) given intermittently via inhalation to subjects with acute bronchiolitis.

Bronchiolitis is defined as an infection of the small airways. It is also the most common manifestation of acute lower respiratory infection (ALRI) in early infancy, and is the leading cause of global child mortality.

Nitric Oxide (NO) has been shown to play a critical role in various biological functions, including in the vasodilatation of smooth muscle, neurotransmission, regulation of wound healing and during immune responses to infection with a microbicidal action directed toward various organisms. In the airways, NO is considered to play a key role in the innate immune system in which the first-line of host defense against microbes is built.

The beneficial effect of NO has been shown in different diseases with several options of doses and regimens; newborn with primary pulmonary hypertension showed improvement in oxygenation after 30 minutes of NO treatment at 10-20 ppm, while subjects with adult respiratory distress syndrome demonstrated clinical improvement during NO treatment at 18 and 36 ppm.

In vitro studies suggested that NO, in part per million (ppm) concentrations, possesses antimicrobial and anti-viral activity against a wide variety of phyla including bacteria, viruses, helminthes and parasites.

Safety and tolerability of 160 ppm NO given intermittently via inhalation were shown in a phase II study performed on 2-12 month infants hospitalized with bronchiolitis. According to data no difference in the proportion of adverse events and serious adverse events were detected between subjects treated with NO and subjects treated with standard supportive treatment.

In this study the investigators wish to assess the efficacy of 160 ppm NO given intermittently via inhalation to 0-12 months-old infants hospitalized due to acute bronchiolitis.

Primary objective: Asses the difference in hospital Length of Stay (LOS) between subjects treated with 160 ppm NO combined with standard supportive treatment and subjects treated with standard supportive treatment.

Secondary objectives: Asses the difference in the time required to achieve clinical improvement, a clinical score ≤5 (Modified Tal score) between subjects treated with 160 ppm NO combined with standard supportive treatment and subjects treated with standard supportive treatment. Assess the difference in the time required to achieve sustained 92% oxygen saturation in room air between subjects treated with 160 ppm NO combined with standard supportive treatment and subjects treated with standard supportive treatment. Characterize the safety and tolerability of 160 ppm NO intermittent inhalation treatment as measure by the rate of adverse events.

In this prospective double-blind, randomized multi-Center study the investigators will enroll up to 120 (no less than 80) subjects aged 0-12 months-old, diagnosed with acute bronchiolitis and requiring in-patient hospitalization.

Enrolled subjects will be randomized into 2 groups. Group 1 -Treatment group - Will receive 160 ppm NO given intermittent via inhalation in addition to standard treatment for up to 5 days. Group 2 - will receive ongoing inhalation of the standard treatment for up to 5 days. Between study and after completing all study inhalations the subject will continue to receive the standard treatment. Oxygen (O2), NO, nitrogen dioxide (NO2) and fraction of inspired oxygen (FiO2) delivered to the patient will be continuously monitored.

Treatment administration: Treatment blindness will be kept by separating between un-blinded team members (giving the actual treatment) and blinded team members, and by hiding the NO container and all study related equipment behind a curtain.

All subjects will return for follow-up visits on day 14(+5), 21(+5) days and will be contacted on day 30 (+5) from day of admission to the department.


Condition or disease Intervention/treatment Phase
Bronchiolitis Drug: Nitric Oxide Other: Supportive treatment Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 69 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Evaluation of the Efficacy Safety and Tolerability of Nitric Oxide Given Intermittently Via Inhalation to Subjects With Bronchiolitis
Actual Study Start Date : March 5, 2017
Actual Primary Completion Date : April 28, 2018
Actual Study Completion Date : April 28, 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Group 1 - Nitric Oxide treatment
• Group 1 (NO treatment) - will receive inhalations of 160 ppm NO combined with O2/air for 30 minutes, every 3-4.5 hours, five times a day (24 hours), for up to 5 days (maximum 25 inhalations), in addition to standard supportive treatment.
Drug: Nitric Oxide
Nitric Oxide given via inhalation in cycles

Other: Supportive treatment
Supportive treatment (including oxygen)

Active Comparator: Group 2 - Control treatment
• Group 2 (Control) - will receive inhalations O2/air using the same treatment schedule and equipment as group 1, in addition to standard supportive treatment.
Other: Supportive treatment
Supportive treatment (including oxygen)




Primary Outcome Measures :
  1. Hospital Length of Stay (LOS) [ Time Frame: 12 days ]
    LOS is measured in hours from the time of first treatment dose to the time of physician decision to discharge.


Secondary Outcome Measures :
  1. Clinical score of ≤5 (Modified Tal score). [ Time Frame: 12 days ]
    The time in hours from first treatment dose, required to achieve a clinical score of ≤5.

  2. Oxygen saturation (SaO2) ≥92% in room air (without oxygen supplementation) sustained for at least 2 hours [ Time Frame: 12 days ]
    The time in hours from first treatment dose, required to achieve SaO2 ≥92% in room air sustained for at least 2 hours.

  3. Adverse events and NO-related adverse events including methemoglobinemia and nitrogen dioxide levels. [ Time Frame: 5 days ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   up to 12 Months   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. 1. Pediatric subjects 0-12-months old.

    a. Including subjects born at ≥28 weeks of gestation.

  2. Subjects with acute bronchiolitis requiring in-patient hospitalization expected for 24 hours and more.
  3. Clinical score of between 7 to 10 at Screening (without oxygen supplementation).
  4. Parent/guardian who is willing and able to sign, an informed consent on behalf of the subject.

Exclusion Criteria:

  1. 1. Subjects diagnosed with alveolar pneumonia on Chest X-ray (including WBC≥ 15,000/ul, and Temp >39°C).
  2. Previous diagnosis of asthma or requirement for asthma medications.
  3. Subjects with >2 previous wheezing episodes.
  4. History of life-threatening respiratory distress that requires admission to an intensive care unit for treatment.
  5. Subjects with history of methemoglobinemia and/or methemoglobin >5% for any cause.
  6. Use of an investigational drug within 30 days before enrolment and/or expected to participate in a new study within 90 days.
  7. History of frequent epistaxis (>1 episode/month) or significant hemoptysis within 30 days prior to enrolment (≥5 mL of blood in one coughing episode or >30 mL of blood in a 24-hour period.
  8. Taken medications such as chronic systemic corticosteroids, CNS stimulants, theophylline or aminophylline, anti-arrhythmic within a certain time period prior to the study.
  9. Unable to comply with the study procedures.
  10. Underlying genetic disorders (including Cystic fibrosis) or hypotonia.
  11. Having the following signs or symptoms: 1) known pulmonary (lung) and/or cardiac (heart) congenital malformations 2) an underlying renal, or liver insufficiency, immunodeficiency, encephalopathy; 3) known or suspected foreign body aspiration.
  12. Any reason that, in the opinion of the investigator, may make the subject unfit for this clinical trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03053388


Locations
Layout table for location information
Israel
Haemek Medical Center
Afula, Israel
Barzili Medical Center
Ashkelon, Israel
Soroka Medical Center
Beer Sheva, Israel
Carmel Medical Center
Haifa, Israel
Rambam Medical Center
Haifa, Israel
Hadassah Medical Center
Jerusalem, Israel
Schneider Children's Hospital
Petah tikva, Israel
Sheba Medical Center
Ramat Gan, Israel
Kaplan Medical Center
Reẖovot, Israel
Tel-Aviv Sourasky Medical Center
Tel Aviv, Israel
Sponsors and Collaborators
Beyond Air Inc.
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Beyond Air Inc.
ClinicalTrials.gov Identifier: NCT03053388    
Other Study ID Numbers: AIT_CP_BRONC02.01
First Posted: February 15, 2017    Key Record Dates
Last Update Posted: July 9, 2019
Last Verified: February 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Bronchiolitis
Respiratory Tract Diseases
Bronchitis
Bronchial Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Tract Infections
Nitric Oxide
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Free Radical Scavengers
Antioxidants
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Endothelium-Dependent Relaxing Factors
Vasodilator Agents
Gasotransmitters
Protective Agents